Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.360 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,736
Open 1.360
Bid (Size) 1.400 (300)
Ask (Size) 1.420 (24,700)
Prev. Close 1.360
Today's Range 1.360 - 1.360
52wk Range 1.120 - 2.980
Shares Outstanding 5,847,955
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's... 
Via Newsfile
News headline image
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway... 
Via Newsfile

Performance

YTD
+1.5%
+1.5%
1 Month
+1.5%
+1.5%
3 Month
-27.3%
-27.3%
6 Month
-21.4%
-21.4%
1 Year
-22.3%
-22.3%

More News

Read More
News headline image
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
Via Newsfile
News headline image
OS Therapies Enters into Warrant Inducement Agreements
Via Newsfile
News headline image
OS Therapies Provides First Half 2026 Corporate Outlook
Via Newsfile
Topics Regulatory Compliance
Market Signals Highlight Next Wave of Immunotherapy Growth (OSTX, IBRX)
Via AB Newswire
News headline image
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
Via Newsfile
News headline image
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25
Via Newsfile
News headline image
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
Via Newsfile
News headline image
OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Via Newsfile
News headline image
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate ↗
Via Benzinga
News headline image
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
Via Newsfile
News headline image
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
Via Newsfile
News headline image
OS Therapies to Participate in Fall 2025 Conferences and Events
Via Newsfile
News headline image
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Via Newsfile
News headline image
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
Via Newsfile
News headline image
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Via Newsfile
Topics Death
News headline image
Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)
Via Newsfile
News headline image
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
Via Newsfile

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?
Yes, OS Therapies Incorporated Common Stock is publicly traded.
What exchange does OS Therapies Incorporated Common Stock trade on?
OS Therapies Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for OS Therapies Incorporated Common Stock?
The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange
What is the current price of OS Therapies Incorporated Common Stock?
The current price of OS Therapies Incorporated Common Stock is 1.360
When was OS Therapies Incorporated Common Stock last traded?
The last trade of OS Therapies Incorporated Common Stock was at 01/30/26 08:00 PM ET
What is the market capitalization of OS Therapies Incorporated Common Stock?
The market capitalization of OS Therapies Incorporated Common Stock is 7.95M
How many shares of OS Therapies Incorporated Common Stock are outstanding?
OS Therapies Incorporated Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.